To conclude, our data demonstrate the importance of rebalancing bile acid signaling at the enterohepatic rather than at the peripheral level, showing that the enterohepatic agonism of TGR5 has the potential to improve NASH and associated glucose dysmetabolism in a preclinical model of MAFLD. Here, GPBAR1 is linked to metabolic dysfunction-associated steatohepatitis.